Fallopian Tube Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Fallopian Tube Cancer Pipeline Insight, 2024," report provides comprehensive insights about 70+ Fallopian tube cancer companies and 70+ pipeline drugs in Fallopian Tube Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. Fallopian tube cancer pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Fallopian Tube Cancer Pipeline Report
• DelveInsight's Fallopian Tube Cancer pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Fallopian Tube Cancer treatment.
• The leading Fallopian Tube Cancer Companies working in the market include ImmunoGen, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab, Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, Genelux Corporation, OncoC4, Inc., CanariaBio Inc., Zentalis Pharmaceuticals, Artios Pharma, ImmunoGen, Inc., Shattuck Labs, Transgene, Sutro Biopharma, Mersana Therapeutics, Rhizen Pharmaceuticals, Atrecsa, Inc., and others.
• Promising Fallopian Tube Cancer Therapies in the various stages of development include Trabectedin, DOXIL, Dexamethasone, epothilone b, CP-547,632, Avastin, Docetaxel, and others.
• May 2024:- University of Colorado, Denver- A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer. The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
• May 2024:- Imunon- Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer. This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
• May 2024:- Bristol-Myers Squibb- A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.

Request a sample and discover the recent advances in Fallopian Tube Cancer @ Fallopian Tube Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Fallopian Tube Cancer Overview
Fallopian Tube Cancer starts in the fallopian tubes, which connect a woman's ovaries to their uterus. Fallopian Tube Cancer is very rare. Only about 1% of all reproductive cancers in women start in the fallopian tubes. The causes and risk factors for developing primary Fallopian Tube Cancer are not known. In some cases, a woman may have a history of chronic infection and/or inflammation of the fallopian tubes (due to untreated sexually transmitted diseases, for example).

The Fallopian Tube Cancer treatment will take into account the patient's stage of the disease, medical history, current health and personal preference, and other factors. The goal of the treatment of Fallopian Tube Cancer is to get rid of the cancer completely with minimal side effects.

Fallopian Tube Cancer Emerging Drugs Profile

• Mirvetuximab Soravtansine: ImmunoGen
Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4. It is currently in phase III stage of development and is being developed by Immunogen.

• Tisotumab vedotin: Genmab/Seagen
Tisotumab vedotin is designed to target tissue factor (TF) using our proprietary antibody-drug conjugate (ADC) technology. TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial, and lung tumors. Tisotumab vedotin is being developed in collaboration with Genmab. It is composed of Genmab's human monoclonal antibody (mAb) that binds to TF and Seagen's ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE). It is currently in phase III stage of development.

• Pembrolizumab: Merck & Co.
Keytruda (pembrolizumab) is a drug developed by Merck used in cancer therapy. It is a monoclonal antibody, a protein that binds to specific ligands, which increases the ability of the immune system to help detect and fight tumor cells. Keytruda has already been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancers including melanoma, non-small cell lung cancer, recurrent or metastatic head and neck cancer, classical Hodgkin lymphoma, and urothelial carcinoma. The drug is still under investigation for the treatment of ovarian cancer, Fallopian tube cancer and several other potential disease.

Learn more about Fallopian Tube Cancer in clinical trials @ Fallopian Tube Cancer Drugs- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Fallopian Tube Cancer Therapeutics Assessment
There are approx. 70+ key Fallopian Tube Cancer companies which are developing the Fallopian Tube Cancer therapies. The companies which have their Fallopian Tube Cancer drug candidates in the most advanced stage, i.e. Phase III include, Immunogen.

DelveInsight's report covers around 70+ Fallopian Tube Cancer products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Discover more about Fallopian Tube Cancer in development @ Fallopian Tube Cancer Clinical Trials- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Fallopian Tube Cancer Companies
ImmunoGen, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab, Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, Genelux Corporation, OncoC4, Inc., CanariaBio Inc., Zentalis Pharmaceuticals, Artios Pharma, ImmunoGen, Inc., Shattuck Labs, Transgene, Sutro Biopharma, Mersana Therapeutics, Rhizen Pharmaceuticals, Atrecsa, Inc., and others.

Fallopian Tube Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Fallopian Tube Cancer Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

To know more about Fallopian Tube Cancer, visit @ Fallopian Tube Cancer Segmentation- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Fallopian Tube Cancer Pipeline Report
• Coverage- Global
• Fallopian Tube Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Fallopian Tube Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Fallopian Tube Cancer Companies- ImmunoGen, OncXerna Theraputics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab, Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, Tmunity Therapeutics, Genelux Corporation, OncoC4, Inc., CanariaBio Inc., Zentalis Pharmaceuticals, Artios Pharma, ImmunoGen, Inc., Shattuck Labs, Transgene, Sutro Biopharma, Mersana Therapeutics, Rhizen Pharmaceuticals, Atrecsa, Inc., and others.
• Fallopian Tube Cancer Therapies- Trabectedin, DOXIL, Dexamethasone, epothilone b, CP-547,632, Avastin, Docetaxel, and others.

For further information on the Fallopian Tube Cancer Pipeline Therapeutics, reach out @ Fallopian Tube Cancer Products Development- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Fallopian Tube Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Fallopian Tube Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Fallopian Tube Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Mirvetuximab Soravtansine: ImmunoGen
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Gimatecan: Lee's Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. TG4050: Transgene
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Fallopian Tube Cancer Key Companies
20. Fallopian Tube Cancer Key Products
21. Fallopian Tube Cancer- Unmet Needs
22. Fallopian Tube Cancer- Market Drivers and Barriers
23. Fallopian Tube Cancer- Future Perspectives and Conclusion
24. Fallopian Tube Cancer Analyst Views
25. Fallopian Tube Cancer Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.